HC Wainwright Brokers Reduce Earnings Estimates for BLSM

Key Points

• HC Wainwright lowered BlossomHill Therapeutics’ Q3 2026 EPS estimate to a loss of $0.93 from $0.92, while maintaining a “Buy” rating and $35 price target. The firm forecasts losses of $0.92 per share for Q4 2026 and $4.75 for full-year 2026.
• BlossomHill reported a quarterly loss of $8.75 per share, missing the consensus estimate of a $0.84 loss by $7.91.
• Analyst sentiment remains favorable, with five Buy ratings and one Hold rating and a consensus price target of $35.00. Insiders have also purchased 1.57 million shares worth approximately $25.2 million over the past three months.

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM - Free Report) - Equities researchers at HC Wainwright decreased their Q3 2026 earnings estimates for shares of BlossomHill Therapeutics in a research report issued to clients and investors on Thursday, September 24th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.93) per share for the quarter, down from their previous forecast of ($0.92). HC Wainwright has a "Buy" rating and a $35.00 price target on the stock. The consensus estimate for BlossomHill Therapeutics' current full-year earnings is ($5.54) per share. HC Wainwright also issued estimates for BlossomHill Therapeutics' Q4 2026 earnings at ($0.92) EPS and FY2026 earnings at ($4.75) EPS.

BlossomHill Therapeutics (NASDAQ:BLSM - Get Free Report) last posted its quarterly earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91).

A number of other research firms also recently weighed in on BLSM. Zacks Research raised BlossomHill Therapeutics to a "hold" rating in a research report on Wednesday, September 2nd. JPMorgan Chase & Co. started coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They issued an "overweight" rating and a $28.00 price target for the company. Wall Street Zen upgraded BlossomHill Therapeutics to a "hold" rating in a research report on Saturday, August 15th. Lifesci Capital assumed coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an "outperform" rating and a $32.00 price objective on the stock. Finally, Guggenheim boosted their price objective on BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a "buy" rating in a research report on Monday, September 21st. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $35.00.

BlossomHill Therapeutics Price Performance

Shares of BLSM opened at $19.75 on Monday. BlossomHill Therapeutics has a 52 week low of $15.25 and a 52 week high of $27.99.

Insider Buying and Selling at BlossomHill Therapeutics

In other news, Director Carl L. Gordon purchased 625,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the acquisition, the director directly owned 2,714,279 shares of the company's stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director John P. Schmid purchased 6,000 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the completion of the transaction, the director owned 6,000 shares of the company's stock, valued at approximately $96,000. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 1,573,900 shares of company stock worth $25,181,900 over the last three months.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.